At What Age Should I Be Screened for Prostate Cancer? A 2026 UK Patient Guide

Written by Mr Neil Haldar, Consultant Urological Surgeon. GMC 3683914. Last reviewed: [May 2026].

Key facts at a glance

• The UK has no current national screening programme for prostate cancer, but men aged 50 and over can request a PSA test from their GP through the NHS informed choice pathway, regardless of symptoms.
• From 2026, the UK is expected to introduce its first ever targeted prostate cancer screening programme, for men with confirmed BRCA1 or BRCA2 gene mutations aged 45 to 61, every two years.
• Black men have around double the lifetime risk of prostate cancer (approximately 1 in 4) compared with the general male population (1 in 8).
• Men with a father or brother diagnosed with prostate cancer have approximately 2 to 2.5 times the average lifetime risk.
• The PSA test is imperfect. Most men with a raised PSA do not have prostate cancer, and some men with prostate cancer have a normal PSA.
• The mpMRI-first pathway, now standard NHS practice, has dramatically reduced unnecessary biopsies and improved detection of significant cancer.

Why this question matters

Prostate cancer is the most common cancer in men in the UK. Around 55,000 new cases are diagnosed each year and approximately 12,000 men die from the disease annually. The lifetime risk is approximately 1 in 8 for the general male population, rising to around 1 in 4 for men of Black ethnicity, and higher still for men with a strong family history or a known BRCA1/BRCA2 mutation.

Most early prostate cancers cause no symptoms. By the time symptoms develop, the cancer is often more advanced and harder to cure. This is the central rationale for screening — to find aggressive cancers earlier, when treatment is most effective. But screening also has real harms: false positives, unnecessary biopsies, and the over-diagnosis of slow-growing cancers that would never have caused trouble. The right age to start screening, and indeed whether to screen at all, depends on a careful weighing of these competing considerations against your personal risk.

Is there a UK national screening programme for prostate cancer?

The short answer: not yet, but this is changing in 2026 for one specific group.

For decades, the UK has not operated a national prostate cancer screening programme, in contrast to the breast, bowel, and cervical screening programmes. The reason has been that the PSA test, used as a population screening tool, finds too many cancers that would never have caused harm and misses some that would. The most rigorous UK trial of population PSA screening, the CAP trial, found that one-off PSA testing did not significantly reduce prostate cancer deaths.

In November 2025, the UK National Screening Committee (UK NSC) published draft recommendations that mark the most significant shift in UK screening policy for prostate cancer in over twenty years. The Committee proposed:

• A targeted national screening programme for men with confirmed BRCA1 or BRCA2 mutations, offering PSA testing every two years from age 45 to age 61.
• No recommendation for population-wide screening for all men.
• No targeted screening for Black men or men with a family history, citing continuing uncertainty over the balance of benefit and harm.

The final recommendation was due at the UK NSC’s meeting on 26 March 2026. If approved by the four UK governments, this will be the first national prostate cancer screening programme the UK has ever had, though it covers a small fraction of men at increased risk.

Major charities including Prostate Cancer UK and Prostate Cancer Research have publicly disagreed with the decision not to recommend screening for Black men or men with family history. They argue that the modelling underestimates the benefits of screening these groups and that the absence of a programme leaves the men at highest risk reliant on opportunistic GP-initiated testing. This debate is ongoing and may change UK policy further once results from the £42 million TRANSFORM trial — the largest UK prostate cancer screening study in a generation — become available.

The current NHS pathway: PSA on request from age 50

If you are a man aged 50 or over, you are entitled to request a PSA blood test from your GP, even if you have no symptoms. This is sometimes called the “informed choice” pathway. Your GP will:

• Discuss the benefits and limitations of testing with you.
• Provide written information about what an abnormal result might mean.
• Arrange the blood test if you decide to proceed.
• Discuss next steps with you if your PSA is raised.

A PSA result of 3.0 ng/mL or higher is generally considered abnormal for men over 50, although the threshold is age-adjusted (slightly lower for younger men, higher for older men) and should always be interpreted alongside other clinical information.

When should you start thinking about PSA testing?

There is no single right answer — it depends on your personal risk profile. The framework I use in clinic is broadly as follows.

Average-risk men

For men with no family history of prostate cancer, no known genetic predisposition, and not of Black ethnicity, the optimal window for considering PSA testing is generally age 50 to 70. Testing before 50 has limited yield except in specific high-risk groups; testing after 70 carries an increasing risk of finding cancers that would never have caused harm. A reasonable starting point is to discuss PSA testing with your GP at around age 50.

Black men

Men of Black African or Black Caribbean ethnicity have approximately double the lifetime risk of prostate cancer compared with the general male population, often present at a younger age, and are more likely to develop aggressive disease. The current consensus among UK urologists — though notably not yet endorsed by the UK NSC — is that Black men should consider starting PSA testing from age 45, with annual or biennial testing if results are normal. This is the position taken by most major UK prostate cancer charities and by international urological associations.

Men with a family history

If your father or brother was diagnosed with prostate cancer (particularly if before age 60), your lifetime risk is approximately 2 to 2.5 times the average. The risk is higher still if multiple first-degree relatives are affected, or if there is also a strong family history of breast, ovarian, or pancreatic cancer (which can suggest an underlying BRCA mutation). Most UK urologists recommend considering PSA testing from age 45 for men with a relevant family history.

BRCA1 and BRCA2 mutation carriers

If you carry a confirmed BRCA1 or BRCA2 gene mutation, you fall into the highest-risk group recognised by the UK NSC. Men with BRCA2 mutations in particular develop more aggressive prostate cancers at younger ages. From 2026, men in this group are expected to be invited for PSA testing every two years from age 45 to 61 through the new targeted national screening programme. Some specialists, including those at the Institute of Cancer Research, have argued for annual rather than biennial testing and for a longer age range — these debates are ongoing.

Men under 45

For men under 45, routine PSA testing is not recommended unless you fall into a very high-risk category (such as a known BRCA mutation, or multiple first-degree relatives with prostate cancer at a young age). However, a single baseline PSA at age 45 can be informative, as research has shown that the PSA value at this age is a reasonable predictor of long-term prostate cancer risk and can guide future testing frequency.

When should you stop or reduce PSA testing?

This is one of the most important and least discussed aspects of prostate cancer screening. The benefit of finding a cancer depends on whether treating it would extend your life or improve its quality. Beyond a certain age — or in the presence of significant other illnesses — finding a slow-growing cancer is more likely to lead to unnecessary investigations and treatments than to extend your life.

The general principle is that routine PSA testing is not recommended once life expectancy is less than 10 to 15 years. In practice, this means:

• Men aged 70 to 75 who are fit, active, and likely to live another 10 to 15 years can reasonably continue testing if they wish, after a careful conversation about the trade-offs.
• Men aged 75 and over rarely benefit from PSA testing, as around 75% of prostate cancer deaths occur in this age group, and the cancers most likely to be found are slow-growing ones that would not affect life expectancy.
• Men with serious other illness (advanced heart disease, dementia, other cancers) should generally not have routine PSA testing, regardless of age.

This is a conversation worth having with your GP rather than a rule to follow blindly.

Understanding PSA test results

PSA stands for prostate-specific antigen, a protein produced by the prostate that leaks into the bloodstream in small amounts. The PSA blood test measures the concentration of this protein.

PSA can be raised by many things other than cancer, including:

• Benign prostatic hyperplasia (BPH) — the natural enlargement of the prostate with age.
• Urinary tract infection or prostatitis (inflammation of the prostate).
• Ejaculation within the past 48 hours.
• Vigorous exercise, particularly cycling.
• Recent catheterisation or prostate examination.

Most men with a raised PSA do not have prostate cancer. If your PSA is mildly raised, your GP will typically:

1. Repeat the test after 6 to 8 weeks, with the standard preparation (no ejaculation, vigorous cycling, or catheterisation in the preceding 48 hours).
2. If still raised, refer you under the NHS two-week-wait suspected cancer pathway.
3. You will then be seen by a urologist who will arrange a multiparametric MRI scan (mpMRI) of the prostate before any biopsy is considered.

The mpMRI-first pathway has transformed UK prostate cancer diagnosis. Up to 30% of men with raised PSA can now safely avoid biopsy because the MRI is reassuring, and when biopsy is needed, MRI guidance allows it to be more targeted and accurate. This is a major improvement on the previous system of “blind” biopsies for everyone with raised PSA.

The benefits and risks of PSA testing

Benefits

• Earlier detection of significant prostate cancer, when curative treatment is most effective.
• Reduced risk of presenting with advanced or metastatic disease.
• Reassurance for men whose PSA remains stable over time.
• The European Randomised Study of Screening for Prostate Cancer (ERSPC) demonstrated a roughly 20% reduction in prostate cancer mortality with regular PSA screening over 16 years.

Risks

• False positives: a raised PSA without cancer, leading to anxiety, repeat tests, and sometimes biopsy.
• False negatives: a normal PSA in the presence of cancer, leading to false reassurance.
• Over-diagnosis: finding slow-growing cancers that would never have caused harm.
• Over-treatment: treating those slow-growing cancers, with side effects including urinary incontinence, erectile dysfunction, and bowel symptoms.

The mpMRI pathway and the much wider use of active surveillance — where low-risk cancers are monitored rather than treated — have substantially reduced these harms compared with the era when most published screening trials were conducted. This is part of why the screening question is being actively reconsidered by UK policymakers in 2026.

What does the evidence actually show?

Two major trials shape our understanding:

The European Randomised Study of Screening for Prostate Cancer (ERSPC) followed over 180,000 men across multiple countries. Regular PSA screening reduced prostate cancer mortality by approximately 20% over 16 years. However, around half of cancers detected through screening were considered over-diagnosed.

The UK ProtecT trial followed nearly 1,650 men with screen-detected localised prostate cancer randomised to surgery, radiotherapy, or active monitoring. At 15 years of follow-up, prostate cancer-specific survival was very high (97%) and similar across all three groups. However, men managed with active monitoring had significantly higher rates of disease progression and metastasis (around 9.4% versus around 4.7% with treatment). This nuanced finding — equivalent survival but more disease progression with active monitoring — is often summarised too simply as “no difference between treatments.” The reality is more textured and continues to inform individual treatment decisions.

Emerging advances in prostate cancer screening

The screening landscape is changing rapidly, and several developments may meaningfully improve the benefit-harm balance in the coming years:

• The TRANSFORM trial, launched in November 2025 with £42 million of funding from Prostate Cancer UK and the UK government, is recruiting 300,000 men to compare four different screening strategies including PSA, biparametric MRI, and a saliva-based polygenic risk test. Initial results are expected within 2 years; full results may take a decade.
• Polygenic risk scores — combining hundreds of genetic markers to estimate individual risk — are showing promise as a way to identify men at genuinely elevated risk for targeted testing. A 2024 saliva-based polygenic risk test was reported to be more accurate than PSA or MRI alone in some early studies.
• BRCA testing is becoming more widely available through the NHS Genomic Medicine Service for men with a relevant personal or family history.
• Newer biomarkers such as the Prostate Health Index (PHI), 4Kscore, and SelectMDx may improve risk stratification when used alongside or instead of PSA.
• Artificial intelligence-assisted MRI interpretation may further improve cancer detection while reducing unnecessary biopsies.

None of these has yet replaced PSA in routine UK practice, but the next decade is likely to see substantial change in how prostate cancer screening is delivered.

What should you discuss with your GP?

If you are considering PSA testing, your GP can help you make an informed decision. Useful topics to cover:

• Your age, ethnicity, and family history of cancer (prostate, breast, ovarian, pancreatic).
• Whether genetic testing for BRCA1/BRCA2 might be appropriate.
• The benefits and limitations of PSA in your specific situation.
• What would happen if your PSA came back raised — referral, MRI, possible biopsy, and the realistic likelihood at each step.
• How often to repeat the test if your initial result is normal.
• Whether you would actually want treatment if a slow-growing cancer were found — this is genuinely worth thinking about in advance.

If you decide to proceed, ask your GP specifically for a PSA test as part of the NHS informed choice pathway. You should be given written information explaining the benefits, limitations, and possible next steps before the test is done.

The bottom line

For most men in the UK, prostate cancer testing is not a matter of being invited to a national programme — at least not yet. It is a matter of an individual conversation with your GP, ideally informed by your personal risk profile.

The framework I would suggest for thinking about it:

• If you are an average-risk man aged 50 to 70, PSA testing is reasonable to consider after a discussion of benefits and harms.
• If you are Black, or have a father or brother with prostate cancer, consider starting from age 45.
• If you have a known BRCA1 or BRCA2 mutation, you are likely to be invited into the new targeted national screening programme from 2026 onwards. In the meantime, raise the issue with your GP — testing every 1 to 2 years from age 45 is appropriate.
• If you are over 75 or have significant other illness, the harms of testing typically outweigh the benefits.
• Whatever your age, new urinary symptoms, blood in the urine, bone pain, or unintended weight loss warrant prompt assessment regardless of PSA testing status.

The question is not really “should I be screened?” in isolation. It is “given who I am, what I value, and what the alternatives look like, does PSA testing offer me more benefit than harm?” That is a conversation worth having properly, not rushed in the last five minutes of a GP appointment.

---

Frequently asked questions

Book a consultation

If you have a raised PSA, a family history of prostate cancer, a known BRCA mutation, or simply want a specialist conversation about your risk and testing options, my secretary can arrange a consultation. NHS referrals to my service at Buckinghamshire Healthcare NHS Trust can be made through your GP.

Contact: Emma Stacey, 07841 048975

---

About the author

Mr Neil Haldar is a Consultant Urological Surgeon specialising in robotic prostatectomy, uro-oncology and paediatric urology.

He has over 25 years’ experience and treats patients across the UK and internationally for complex urological conditions, minimally invasive surgery and expert second opinions.

---

This article is intended for general information only and does not replace individual medical advice. Screening recommendations are evolving rapidly in the UK, and the position outlined here reflects guidance and expert consensus as of April 2026. Decisions about PSA testing should always be made in consultation with your GP or specialist team, taking your individual circumstances into account.